Business model and market
Abacus Medicine is a distributor of original prescription medicines. Our business model is based on the core principle of the free movement of goods in the EU’s single market.
Currency rates and the price setting of original manufactures often make exactly the same medicine available at different prices in different EU-countries. This allows Abacus Medicine to purchase the medicine in a low-cost country and make a profit by reselling it in a high-cost country. This is generally known as parallel distribution or parallel import.
The total market for parallel distribution of medicines in Europe amounts to approximately 5.5 billion euro. The most important country is Germany, which accounts for roughly half of the total market. Because healthcare systems and national reimbursement rules differ substantially from country to country, a deep knowledge of each individual market is a cornerstone in the success of Abacus Medicine.
Healthcare costs are rising
We are living longer. Children born in Western Europe in 2017 have an average life expectancy of 79 years for males and 84 years for females. This is a lot higher, than it used to be.
Since 1970, the average life expectancy of a citizen of Germany has risen 10.1 years and 14.5 years for people in Portugal. In other parts of the world, life expectancy has risen even more. (1)
People living longer, happy lives is obviously a cause for joy. But it comes at a cost: It is often very expensive. The proportion of elderly is growing in all EU member states, and our changing demographics has sent healthcare costs soaring with seemingly no end in sight.
Already, we are beginning to see our societies straining to bear the burden. Hospitals are laying off staff to pay for expensive medicine, and the money spent on healthcare cannot be spent on other things we might value. Better schools, safer roads, or protecting the environment, for example.
When Abacus Medicine supplies medicines at a more affordable price, the result is significant savings for patients and the public budgets. A number of studies (2) have shown that parallel imports of medicine create direct and indirect savings worth billions of euro annually.
Our strategy
Abacus Medicine is a market leader in the most expensive types of medicines such as chemotherapies for cancer treatment or immunosuppressive drugs used in connection with organ transplants. Prices of 3,000 euros or more are standard for these medicines.
We pursue an ambitious growth strategy through selling many types of medicines in many different countries. We invest heavily in entering new markets and in increasing the number of medicines, we hold a license to sell. The majority of our competitors focus on fewer and less expensive products in a few or even a single country.
Our presence in many different markets adds complexity to our business. To navigate this complexity we have developed advanced methods and IT systems for analysing Big Data in real time. This creates an important competitive advantage as it allows us to buy and sell on the right markets, operate efficiently in logistics and production, and reduce risk by limiting our stocks of expensive medicines.
This approach has been uniquely value-creating. Year after year, Abacus Medicine has reported strong, organic growth coupled with sound profitability above the industry average.
Today, you will find our offices and more than 450 people in several countries.
Timeline
Abacus Medicine is a young company that has come far in a short time. Browse through the main events of our journey below.
2004
Abacus Medicine is founded by father and son: John and Flemming Wagner
2006
First deliveries to Danish pharmacies and hospitals
2009
Abacus Medicine becomes the largest parallel importer of medicine to the Danish hospital network
2010
Beyond borders: Sweden becomes our first export market
2012
Abacus Medicine Hungary is established
First deliveries to Germany
2014
First deliveries in the Netherlands
2015
First deliveries in the UK and in Austria.
Launch of DayDose
2016
Turnover exceeds 1 billion DKK
First deliveries in France and Finland
empty_end
DayDose is an advanced dietary supplement made super simple.
As a consumer brand, it is also a new and exciting type of business venture for Abacus Medicine.
We manufacture and sell the DayDose supplements directly to consumers and high street retailers.
Contact
We are happy to help, so please get in touch. Below you will find our main offices, but we have people covering all of Europe.
Vesterbrogade 149
1620 Copenhagen V
Denmark
Wolfgang-Pauli-Gasse 5/1/1/6
A-1140 Wien
Österreich
Berliner Straße 8
D-16727 Velten
Deutschland
Fleet Street 107
EC4A2AB London
United Kingdom
Orioninitie 5
02200 Esbo
Finland
12/14 Rond-Point des Champs-Elysées
Paris 75008, France
Herculesstraat 25
1812 PD Alkmaar
Holland
Jedes Fokusprogramm hat spezifische Ziele, sowie einen separaten Action Plan. Die Anzahl an Fokusprogrammen variiert von Jahr zu Jahr.